Fluocinolone acetonide implant effective in treating diabetic macular edema: BMJ
USA: The use of the 0.2 ug/day fluocinolone acetonide (FAc) implant is beneficial for the management of diabetic macular edema, a recent study in the British Journal of Ophthalmology has found. According to the study, following 24 months of FAc implant, there were few intraocular pressure (IOP)-related procedures. Also, there was a stabilization of vision and reduction in inflammation.
Approximately 35% of the diabetes patients develop diabetic retinopathy and 7% progress to diabetic macular edema (DMO) which a severe vision-threatening stage of diabetic retinopathy. The FAc implant delivers continuous, low-dose, intravitreal corticosteroid for the treatment of diabetic macular edema.
Sam E Mansour, George Washington University, Washington, District of Columbia, USA, and colleagues conducted this his 24-month interim analysis of a prospective, observational study to investigate patients with DMO receiving the commercially available intravitreal 0.2 µg/day FAc implant. Data were collected from 95 previously steroid-challenged patients (115 study eyes) for up to 36 months pre-FAc and 24 months post-FAc implant.
The primary outcome was incidence of intraocular pressure (IOP)-lowering procedures.
Key findings of the study include:
- Mean IOP for the overall population remained stable post-FAc compared with pre-FAc implant.
- IOP-related procedures remained infrequent (two IOP-lowering surgeries pre-FAc; two trabeculoplasties and four IOP-lowering surgeries post-FAc).
- Mean visual acuity was stable post-FAc (mean improvement of 1–3 letters) and fewer DMO treatments were required per year following FAc implant.
- Mean CST was significantly reduced at 24 months post-FAc implant and the percentage of patients with CST ≤300 µm was significantly increased.
"Few IOP-related procedures were reported during the 24 months post-FAc implant. Positive efficacy outcomes were noted after treatment, with stabilization of vision and reduction in inflammation, demonstrated by CST. The FAc implant has a favorable benefit-risk profile in the management of DMO, especially when administered after a prior steroid challenge," concluded the authors.
"Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study," is published in the British Journal of Ophthalmology.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.